Clinical Trials

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy


Study ID
Merck MK-3475-057

NCT Number
NCT02625961 (Click on the NCT number for more information about the trial)

Research Study Number
0006369

Principle Investigator
Dr. Robert Alter

Phase
II

Sponsor
Merck


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now